Literature DB >> 29284661

Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Alyssa F Collier1, Jessica Gumerson1, Kimmo Lehtimäki1, Jukka Puoliväli1, Jace W Jones1, Maureen A Kane1, Sankeerth Manne1, Andrea O'Neill1, Hillarie P Windish1, Toni Ahtoniemi1, Bradley A Williams1, Douglas E Albrecht1, Robert J Bloch2.   

Abstract

Ibuprofen, a nonsteroidal anti-inflammatory drug, and nitric oxide (NO) donors have been reported to reduce the severity of muscular dystrophies in mice associated with the absence of dystrophin or α-sarcoglycan, but their effects on mice that are dystrophic due to the absence of dysferlin have not been examined. We have tested ibuprofen, as well as isosorbide dinitrate (ISDN), a NO donor, to learn whether used alone or together they protect dysferlin-null muscle in A/J mice from large strain injury (LSI) induced by a series of high strain lengthening contractions. Mice were maintained on chow containing ibuprofen and ISDN for 4 weeks. They were then subjected to LSI and maintained on the drugs for 3 additional days. We measured loss of torque immediately following injury and at day 3 postinjury, fiber necrosis, and macrophage infiltration at day 3 postinjury, and serum levels of the drugs at the time of euthanasia. Loss of torque immediately after injury was not altered by the drugs. However, the torque on day 3 postinjury significantly decreased as a function of ibuprofen concentration in the serum (range, 0.67-8.2 µg/ml), independent of ISDN. The effects of ISDN on torque loss at day 3 postinjury were not significant. In long-term studies of dysferlinopathic BlAJ mice, lower doses of ibuprofen had no effects on muscle morphology, but reduced treadmill running by 40%. Our results indicate that ibuprofen can have deleterious effects on dysferlin-null muscle and suggest that its use at pharmacological doses should be avoided by individuals with dysferlinopathies.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29284661      PMCID: PMC5801553          DOI: 10.1124/jpet.117.244244

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

1.  CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.

Authors:  Xi Yin; Qian Wang; Ting Chen; Junwei Niu; Rui Ban; Jiexiao Liu; Yanling Mao; Chuanqiang Pu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.

Authors:  Clara Sciorati; Roberta Buono; Emanuele Azzoni; Silvana Casati; Pierangela Ciuffreda; Grazia D'Angelo; Dario Cattaneo; Silvia Brunelli; Emilio Clementi
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

4.  Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation.

Authors:  E M McNally; C T Ly; H Rosenmann; S Mitrani Rosenbaum; W Jiang; L V Anderson; D Soffer; Z Argov
Journal:  Am J Med Genet       Date:  2000-04-10

5.  Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis.

Authors:  T A Trappe; F White; C P Lambert; D Cesar; M Hellerstein; W J Evans
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

6.  Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Jennifer Manning; Rebecca Kulbida; Prerana Rai; Lindsay Jensen; Judith Bouma; Sanjay P Singh; Dervla O'Malley; Deniz Yilmazer-Hanke
Journal:  Exp Physiol       Date:  2014-06-27       Impact factor: 2.969

7.  Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

Authors:  Silvia Brunelli; Clara Sciorati; Giuseppe D'Antona; Anna Innocenzi; Diego Covarello; Beatriz G Galvez; Cristiana Perrotta; Angela Monopoli; Francesca Sanvito; Roberto Bottinelli; Ennio Ongini; Giulio Cossu; Emilio Clementi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

8.  Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy.

Authors:  J Liu; M Aoki; I Illa; C Wu; M Fardeau; C Angelini; C Serrano; J A Urtizberea; F Hentati; M B Hamida; S Bohlega; E J Culper; A A Amato; K Bossie; J Oeltjen; K Bejaoui; D McKenna-Yasek; B A Hosler; E Schurr; K Arahata; P J de Jong; R H Brown
Journal:  Nat Genet       Date:  1998-09       Impact factor: 38.330

9.  Dysferlinopathy course and sportive activity: clues for possible treatment.

Authors:  C Angelini; E Peterle; A Gaiani; L Bortolussi; C Borsato
Journal:  Acta Myol       Date:  2011-10

10.  Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy.

Authors:  Joseph A Roche; Lisa W Ru; Robert J Bloch
Journal:  J Biomed Biotechnol       Date:  2012-02-06
View more
  2 in total

1.  Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

Authors:  Zoe White; Nadia Milad; Arash Y Tehrani; William Wei-Han Chen; Graham Donen; Stephanie L Sellers; Pascal Bernatchez
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

2.  Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.

Authors:  Natasja de Bruin; Ann-Kathrin Schneider; Philipp Reus; Sonja Talmon; Sandra Ciesek; Denisa Bojkova; Jindrich Cinatl; Imran Lodhi; Bruce Charlesworth; Simon Sinclair; Graham Pennick; William F Laughey; Philip Gribbon; Aimo Kannt; Susanne Schiffmann
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.